Figure 1. Nicotinic acid-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/NIACR1/Gα15 cells. The cells were loaded with Calcium-4 (Cat. No. R8142; Molecular Devices) prior to stimulation with NIACR1 agonist, nicotinic acid. The intracellular calcium change was measured by FLIPR^TETRA. The relative fluorescent units (RFU) were recorded and normalized to plot against the log of the cumulative doses of nicotinic acid (mean ± SEM, n = 3). The EC₅₀ of nicotinic acid on CHO-K1/NIACR1/Gα15 cells was 1.38 nM.

Notes:
EC₅₀ value is calculated with four parameter logistic equation:
Y=Bottom + (Top-Bottom) / (1+10^ ((LogEC₅₀-X)*Hill Slope))
X is the logarithm of concentration. Y is the response.
Y is % stimulation of RFU and starts at Bottom and goes to Top along a sigmoid curve.

Figure 2. Dose dependent stimulation of intracellular cAMP accumulation upon treatment with nicotinic acid in CHO-K1/NIACR1/Gα15 cells. d2 acceptor fluorophore -labeled cAMP (Cat. No. 62AM4PEC; Revvity) and intracellular cAMP in CHO-K1/NIACR1/Gα15 cells competitively bind with Europium Cryptate-labeled anti-cAMP monoclonal antibody. The FRET signal decreases as the intracellular cAMP concentration rises and was measured by plate reader (Pherastar, BMG). The EC₅₀ of nicotinic acid on CHO-K1/NIACR1/Gα15 cells was 10.80 nM.

CHO-K1/NIACR1/Gα15 Stable Cell Line

Recombinant CHO-K1 cells stably overexpress human nicotinic acid receptor (NIACR1), also known as hydroxycarboxylic acid receptor 2 (HCAR2), on the surface and contain high levels of G protein Gαi to couple with the receptor in downstream signaling pathways.

产品编号	M00428
规格	2 vials 大单询价
数量
价格	询价


联系我们

产品简介

Product Description	Recombinant CHO-K1 cells stably overexpress human nicotinic acid receptor (NIACR1), also known as hydroxycarboxylic acid receptor 2 (HCAR2), on the surface and contain high levels of G protein Gαi to couple with the receptor in downstream signaling pathways.
Culture Properties	Adherent
Stability	Stable through more than 16 passages with no significant changes in assay performance or expression profile.
Size	Two vials of frozen cells (>1×10⁶ per vial in 1 mL)
Storage	Store cells in liquid nitrogen immediately upon receipt. Thaw and recover cells within one year from the date received.

培养条件

Culture Medium	Ham’s F-12K (Kaighn’s), 10% FBS, 200 μg/ml Zeocin (Cat. No. R250-01, Life Technologies), 100 μg/ml Hygromycin B (Cat. No. 10687010, Invitrogen)
Complete Growth Medium	Ham’s F-12K (Kaighn’s), 10% FBS
Freeze Medium-DATA	45% Ham’s F-12K (Kaighn’s) (Cat. No. 21127, Life Technologies), 45% FBS (Cat. No. 10099-141, Gibco), 10% DMSO (Cat. No. D2650, Sigma)

图例

Figure 1. Nicotinic acid-induced concentration-dependent stimulation of intracellular calcium mobilization in CHO-K1/NIACR1/Gα15 cells. The cells were loaded with Calcium-4 (Cat. No. R8142; Molecular Devices) prior to stimulation with NIACR1 agonist, nicotinic acid. The intracellular calcium change was measured by FLIPR^TETRA. The relative fluorescent units (RFU) were recorded and normalized to plot against the log of the cumulative doses of nicotinic acid (mean ± SEM, n = 3). The EC₅₀ of nicotinic acid on CHO-K1/NIACR1/Gα15 cells was 1.38 nM.

Notes:
EC₅₀ value is calculated with four parameter logistic equation:
Y=Bottom + (Top-Bottom) / (1+10^ ((LogEC₅₀-X)*Hill Slope))
X is the logarithm of concentration. Y is the response.
Y is % stimulation of RFU and starts at Bottom and goes to Top along a sigmoid curve.

Figure 2. Dose dependent stimulation of intracellular cAMP accumulation upon treatment with nicotinic acid in CHO-K1/NIACR1/Gα15 cells. d2 acceptor fluorophore -labeled cAMP (Cat. No. 62AM4PEC; Revvity) and intracellular cAMP in CHO-K1/NIACR1/Gα15 cells competitively bind with Europium Cryptate-labeled anti-cAMP monoclonal antibody. The FRET signal decreases as the intracellular cAMP concentration rises and was measured by plate reader (Pherastar, BMG). The EC₅₀ of nicotinic acid on CHO-K1/NIACR1/Gα15 cells was 10.80 nM.

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.

CHO-K1/NIACR1/Gα15 Stable Cell Line

资源中心

技术支持

关于我们